Search Results
Your search for ,wAs matches 27466 pages
Showing 15651 - 15700EXPERT POINT OF VIEW: Andrzej Jakubowiak, MD, PhD
INTERVIEWED BY The ASCO Post, Andrzej Jakubowiak, MD, PhD, Director of the Multiple Myeloma Program at the University of Chicago Medical Center, commented on the “controversial findings” of EMN02/HO95. “This European study has opened the gate toward showing the benefit of a second transplant,...
European Study Shows Double Transplant Improves Survival in Myeloma
FOR NEWLY DIAGNOSED patients with multiple myeloma considered to be at high risk of disease progression, double autologous stem cell transplantation (ASCT) significantly prolongs progression-free and overall survival, vs single transplant, according to the phase III EMN02/HO95 study. The findings...
Proud to Be a Pioneer in CAR T-Cell Therapy
Six years ago, I was 38 years old and, like many young people, took life for granted. I had two young daughters, ages 7 years and 4 months, and a wife I adored. And, except for a nagging pain on the left side of my abdomen, I was blessed with good health. Then, suddenly, the pain became so...
Study Uses Music Medicine to Reduce Stress in Pediatric Patients
In a first-of-its-kind collaboration, the Children’s Cancer Association, Randall Children’s Hospital at Legacy Emanuel, and Legacy Research Institute, of Portland, Oregon, co-led a study to assess the impact of using live music as medicine on postoperative pediatric patients to reduce pain and...
TAT 2018: Epigenetics Therapy Shows Promise in Patients With Lymphoma
New compounds targeting epigenetics have shown early activity in patients with lymphoma, according to data presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris. The meeting, which focused on phase I research, featured early clinical studies with BET inhibitors...
Acupuncture for the Management of Chemotherapy-Induced Peripheral Neuropathy
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, reviews the current data on the use of acupuncture...
Lutetium Lu-177 Dotatate in Gastroenteropancreatic Neuroendocrine Tumors
On January 26, 2018, the radiolabeled somatostatin analog lutetium Lu-177 dotatate (Lutathera) was approved for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors, in adults.1,2 Supporting...
PIK3CA Mutation and Prognosis in Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Zardavas et al found that the prognostic effect of PIK3CA mutation in early breast cancer was reduced after adjustment for other prognostic factors. Study Details The study involved analysis of individual patient data from a pooled...
Neoadjuvant Therapy in Triple-Negative Breast Cancer
In a phase III trial (BrighTNess) reported in The Lancet Oncology, Loibl et al found that the addition of the PARP inhibitor veliparib to carboplatin and paclitaxel in neoadjuvant therapy did not increase pathologic complete response rate in women with triple-negative breast cancer. Study Details ...
Gene-Expression Profiling Score for Predicting High- vs Low-Risk of Follicular Lymphoma Progression
As reported in The Lancet Oncology, Huet et al have developed a 23-gene expression profile that predicts risk of follicular lymphoma progression. Study Details In a training cohort consisting of a subgroup of patients from the PRIMA trial (in which rituximab [Rituxan] maintenance was evaluated...
Adjuvant Chemotherapy for Upper Tract Urothelial Cancer
ADJUVANT CHEMOTHERAPY achieved robust improvements in disease-free survival and metastasis-free survival compared with surveillance in the phase III POUT study of patients with upper tract urothelial cancer.1 Further, there was an early trend toward improved overall survival with adjuvant...
Adolescent and Young Adult Cancer Survivors Often Struggle With Reproductive and Sexual Health Concerns
FOR MANY adolescents and young adults (AYAs), the most distressing and troubling phase of the cancer continuum that began with diagnosis is survivorship, and among the toughest challenges are those involving sexual health and reproduction, Jessica Gorman, PhD, MPH, stated at the 11th Annual...
EXPERT POINT OF VIEW: Jordi Bruix, MD, PhD, and Flavio G. Rocha, MD
THE STUDY’S invited discussant, Jordi Bruix, MD, PhD, of the University of Barcelona, Spain, said one of the benefits of the TACTICS study was to evaluate the use of the new unTACEable-based endpoint, which he favors. “The endpoint used in the trial is a good attempt to do something new that may...
In Unresectable Liver Cancer, Progression-Free Survival Doubled When Sorafenib Added to TACE
SORAFENIB (Nexavar) added to transarterial chemoembolization (TACE) doubled the median progression-free survival over TACE alone in patients with unresectable hepatocellular carcinoma, Japanese investigators reported at the 2018 Gastrointestinal Cancers Symposium.1 The results of the randomized,...
Small Study Evaluates Treatment Sequencing in Patients With Metastatic Colorectal Cancer
THE OPTIMAL treatment sequence for two approved agents in metastatic colorectal cancer may be regorafenib (Stivarga) before cetuximab (Erbitux), according to results from the small randomized Japanese REVERCE trial presented at the 2018 Gastrointestinal Cancers Symposium.1 Giving regorafenib...
Investigational Genomic Tool Identifies Consensus Molecular Subtype of Colon Tumor and May Predict Risk of Recurrence
AN INVESTIGATIONAL TOOL called ColotypeR classifies colon cancers by molecular subtype and creates a subtype-specific risk of recurrence, according to research. Developers of the tool say it will be able to guide treatment decisions. Colon cancer is highly heterogeneous in prognosis and response to ...
Small Study Evaluates Novel Immunotherapeutic in Metastatic Pancreatic Cancer
IN PATIENTS WITH metastatic pancreatic adenocarcinoma, 1-year survival reached 43% following treatment with a novel immunotherapy—PEGylated human IL-10 (AM0010, pegilodecakin)—plus chemotherapy, in a small study reported at the 2018 Gastrointestinal Cancers Symposium.1 “We saw a very high disease...
Expression of Endogenous Retroviruses May Explain Response to Immune Checkpoint Therapy in Renal Cell Cancer
RESULTS OF a new study suggest that expression of endogenous retroviruses may be associated with activation of immune checkpoint pathways in renal cell cancer.1 According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, abnormal expression of endogenous retroviruses may...
Combination PARP and PD-1 Inhibition Shows Antitumor Activity in Advanced Malignancies
IN A PHASE I trial of patients with advanced solid tumors, the combination of pamiparib (BGB-290), a selective poly (ADP-ribose) polymerase (PARP) inhibitor, and tislelizumab (BGB-A317), an agent targeting the programmed cell death protein 1 (PD-1) receptor, was well tolerated while demonstrating...
Responses Reported With CAR T-Cell Therapy in High-Risk NHL
LISOCABTAGENE MARALEUCEL (Liso-cel; JCAR017), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy with defined composition, has shown “potent and durable” responses in poor-prognosis patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) in a phase I trial.1 According ...
EXPERT POINT OF VIEW: Philip Kantoff, MD
PHILIP KANTOFF, MD, of Memorial Sloan Kettering Cancer Center, New York, was the formal discussant of both trials. “At first glance, these are two positive trials,” Dr. Kantoff said. Although he praised the results, he said that overall survival is the best demonstration of clinical benefit, and ...
Apalutamide, Enzalutamide Improve Metastasis-Free Survival in Nonmetastatic Castrate-Resistant Prostate Cancer
IN TWO SEPARATE TRIALS presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide (Xtandi), respectively, reduced the risk of metastasis and prolonged metastasis-free survival in men with high-risk nonmetastatic castrate-resistant prostate cancer. In the SPARTAN trial,1,2...
Advancing Cancer Research in Challenging Times
ON OCTOBER 17, 2017, Norman E. Sharpless, MD, became the 15th Director of the National Cancer Institute (NCI), succeeding Harold E. Varmus, MD, who stepped down as Director of the agency in March 2015, and replacing Douglas R. Lowy, MD, who had served as Acting Director for 2 years. The...
EXPERT POINT OF VIEW: Sumanta K. Pal, MD
ASCO EXPERT Sumanta K. Pal, MD, of City of Hope, Duarte, California, commented, “IMmotion 151 is a positive trial and represents an important breakthrough. We have debated combination treatment strategies for advanced kidney cancer. This study looks at the combination of a programmed cell death...
Atezolizumab Plus Bevacizumab Improves Progression-Free Survival in First-Line Treatment of Advanced Renal Cell Carcinoma
THE TYROSINE KINASE inhibitor sunitinib (Sutent) has been the mainstay of treatment for first-line treatment of advanced renal cell carcinoma for about a decade. The IMmotion151 study reported at the 2018 Genitourinary Cancers Symposium found that the combination of the immune checkpoint inhibitor...
New Agents for Initial Treatment of Metastatic Prostate Cancer: A New Standard of Care?
FOR DECADES, the status of metastatic prostate cancer trials was not particularly exciting. With an absence of high-impact novel agents, the focus of cancer trial groups was on the improvement of standard care. Well-crafted, large trials of hormonal therapy demonstrated the utility of combined...
Analysis of Carfilzomib-Related Cardiotoxicity
In a systematic review and meta-analysis reported in Leukemia & Lymphoma, Shah et al identified the risk of cardiotoxicity among patients, most with multiple myeloma, receiving carfilzomib (Kyprolis) in clinical trials. Study Details The study included data from 4,164 patients who received...
Pretreatment Cancer-Associated Weight Loss and Prognosis
In a study reported in the Journal of Oncology Practice, Gannavarapu et al found that substantial unintentional weight loss prior to treatment is common among patients with cancer across stages of disease and is associated with poorer outcome. Study Details The retrospective cohort study included ...
Adjuvant Vemurafenib in Resected BRAF V600–Mutant Melanoma
In the international phase III BRIM8 trial reported in The Lancet Oncology, Maio et al found inconclusive evidence of benefit of adjuvant vemurafenib treatment in patients with BRAF V600–mutant melanoma. Study Details In the double-blind trial, 498 patients with fully resected...
Multimodal Treatment in Patients With Gleason Score 9–10 Prostate Cancer
University of California, Los Angeles (UCLA) researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer. The findings, published by Kishan et al in JAMA, also...
FDA Approves sBLA Updating Nivolumab Dosing Schedule Across Indications
On March 6, Bristol-Myers Squibb announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the nivolumab (Opdivo) dosing schedule to include 480 mg infused every 4 weeks for a majority of approved indications. This approval will ...
Circulating Tumor DNA and Pseudoprogression in Metastatic Melanoma Treated with Anti–PD-1 Antibodies
In a study reported in JAMA Oncology, Lee et al found that measurement of circulating tumor DNA (ctDNA) can help distinguish between pseudoprogression (radiologic progression prior to response) and true progression in patients with metastatic melanoma receiving anti–programmed cell death ...
Upfront Adjuvant Aromatase Inhibitor Therapy vs Aromatase Inhibitors After Tamoxifen in Hormone Receptor–Positive Early Breast Cancer
An Italian phase III trial (FATA-GIM3) has shown no difference in disease-free survival with 5 years of upfront adjuvant aromatase inhibitor therapy vs 2 years of tamoxifen followed by 3 years of aromatase inhibitor therapy in women with hormone receptor–positive early breast cancer. The...
Novel PI3Kδ Inhibitor in Relapsed or Refractory Hematologic Malignancies
In a phase I trial reported in The Lancet Oncology, Burris et al determined the phase II dose of the next-generation PI3Kδ inhibitor umbralisib and found evidence of the agent’s activity in relapsed or refractory hematologic malignancies. Umbralisib exhibits improved PI3K isoform...
Multitargeted Tyrosine Kinase Inhibitor Shows Activity in Small Cell Carcinoma of the Ovary
An multitargeted tyrosine kinase inhibitor used to treat leukemia has shown promise against a rare and aggressive type of ovarian cancer—small cell carcinoma of the ovary hypercalcemic type (SCCOHT)—that strikes young women and girls, according to a study led by the Translational...
Texas Society of Clinical Oncology Makes Investment in Young Investigators
The Texas Society of Clinical Oncology (TxSCO) is one of the newest supporters of the Conquer Cancer Foundation’s Young Investigator Award (YIA) program. A state affiliate of ASCO, TxSCO currently has more than 600 members who represent a diverse array of oncology health providers in Texas. “We are ...
Dexamethasone-Sparing Antiemetic Regimen in Patients Receiving Highly Emetogenic Chemotherapy
In a Japanese phase III noninferiority trial reported in the Journal of Clinical Oncology, Ito et al found that dexamethasone could be spared on days 2 and 3 in an antiemetic regimen including the neurokinin-1 (NK1) receptor antagonist aprepitant and palonosetron in patients receiving highly...
Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors
In a Danish study reported in the Journal of the National Cancer Institute, Zachariae et al found that an Internet-delivered cognitive-behavioral therapy intervention improved insomnia among breast cancer survivors. Study Details In the study, 255 patients from a national sample of Danish breast...
Cognitive Decline Prevalent Among Elderly Patients With Hematologic Cancers
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning—a decline that may impact their survival—a new study by investigators at Dana-Farber Cancer Institute and Brigham and...
Called to Lead: Tara O. Henderson, MD, MPH, Selected for Presidential Leadership Scholars Program
ASCO congratulates pediatric oncologist Tara O. Henderson, MD, MPH, on being selected for the 2018 Presidential Leadership Scholars (PLS) program. This highly competitive and prestigious national program was created to help individuals from many professional backgrounds develop the practical...
Bevacizumab in Recurrent Glioblastoma
On December 5, 2017, bevacizumab (Avastin) was granted regular approval for the treatment of recurrent glioblastoma in adults.1 Bevacizumab was granted accelerated approval in May 2009 for use in treating patients with glioblastoma who had disease progression on prior therapy. Supporting Efficacy...
The Skin Cancer Foundation Announces Office Relocation
The Skin Cancer Foundation, the leading nonprofit organization for public and professional skin cancer education, recently moved to a new office space at 205 Lexington Avenue in midtown Manhattan. The new office will allow the Foundation to grow its staff as it develops new patient support programs ...
Why Right-to-Try Laws Are Dangerous
Why wouldn’t you support a patient with a terminal illness the “right to try” any therapy that may save his or her life? The answer to this question—one engulfed in a political debate in Congress—seems simple. It is not. [Editor’s Note: On May 30, 2018, the President signed into law the Trickett...
Study Finds Colorectal Cancer Screenings Vary Widely Throughout the United States
A study examining prevalence estimates of colorectal cancer screening at the county level in the United States has found that the country is far behind reaching the goal of screening 80% of adults aged 50 and older for colorectal cancer by 2018, which is supported by the National Colorectal Cancer...
Genomic Analyses Highlight Need for Precision Therapies That Target Pediatric Cancers
Researchers have determined that children and adults with cancer often have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative study led by St. Jude Children’s Research Hospital and published by...
Use of Charity Assistance to Pay for Novel Oral Anticancer Agents
In a study reported in the Journal of Oncology Practice, Olszewski et al found that 36% of patients receiving novel oral anticancer agents in a Rhode Island academic research center received charity assistance to pay for treatment, including 47% of patients aged ≥ 65 years. Study Details The...
Chemoradiotherapy vs Neoadjuvant Chemotherapy and Radical Surgery in Locally Advanced Squamous Cervical Cancer
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Gupta et al found that cisplatin-based chemoradiotherapy improved disease-free survival vs neoadjuvant chemotherapy and radical surgery in women with locally advanced squamous cervical cancer. Study Details...
Denosumab vs Zoledronic Acid in Newly Diagnosed Multiple Myeloma With Bone Disease
In a phase III trial reported in The Lancet Oncology, Raje et al found that denosumab was noninferior to zoledronic acid in preventing skeletal-related events (SREs) in newly diagnosed multiple myeloma patients with bone disease. Study Details In the double-blind trial, 1,718 patients with at...
Adjuvant Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer
As reported in the Journal of Clinical Oncology by Wapnir et al, the final analysis of the phase III CALOR trial showed benefit of adjuvant chemotherapy in estrogen receptor (ER)–negative but not ER-positive isolated locoregional recurrence of breast cancer. Study Details In this open-label ...
Body Mass Index and Outcomes With Targeted Therapy, Immunotherapy, or Chemotherapy in Metastatic Melanoma
In a study reported in The Lancet Oncology, McQuade et al found that obesity was associated with improved outcomes in treatment of metastatic melanoma with targeted therapy or immunotherapy—but not chemotherapy—with a survival benefit appearing to be restricted to obese male patients....
